価格表

在庫・価格 : 2024年04月26日 14時40分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-Human B7-H1 MAb (Clone 130021) (100 UG)
データシート※最新のデータシートでない場合があります
MAB1561 RSDアールアンドディー システムス
R&D Systems, Inc.
100 μg ¥104,000
(未発注)
追加

在庫・価格 : 2024年04月26日 14時40分 現在

Anti-Human B7-H1 MAb (Clone 130021) (100 UG)

  • 商品コード:MAB1561
  • メーカー:RSD
  • 包装:100μg
  • 価格: ¥104,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Rojas D et al. IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol. Lett. 2010 Aug;132(1-2):31-7
Rojas D et al
2010/01/01
Application: Flow Cytometry, Sample Type: Whole Cells PubMed
2 Song X et al. Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol. Rep. 2014 Mar;31(3):1191-8
Song X et al
2014/01/01
Application: IHC Paraffin-embedded, Sample Type: Whole Tissue PubMed
3 Kammerer-Jacquet SF et al. Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urol. Oncol. 2017 10;35(10):603.e7-603.e14
Kammerer-Jacquet SF et al
2017/01/01
Species: Human, Applications: IHC-P PubMed
4 Zhou J et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 2017 Jun;5(6):480-492
Zhou J et al
2017/01/01
Species: Human, Applications: ELISA Capture PubMed
5 Cristiani CM et al. Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunol Res 2019 05;7(5):841-852
Cristiani CM et al
2019/01/01
PubMed
6 Kammerer-Jacquet SF et al. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. Int. J. Cancer 2017 Jan;140(1):142-148
Kammerer-Jacquet SF et al
2017/01/01
PubMed
7 Giampieri R et al. Clinical impact of different exosomes&quot; protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE 2019;14(5):e0215990
Giampieri R et al
2019/01/01
PubMed
8 Mazel M et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015 Nov;9(9):1773-82
Mazel M et al
2015/01/01
PubMed
9 Mocan T et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol 2021 May;94:107467
Mocan T et al
2021/01/01
Species: Human, Applications: IHC PubMed
10 Acheampong E et al. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells 2020 10;9(11)
Acheampong E et al
2020/01/01
Species: Human, Applications: IHC PubMed
  • No.: 1
  • 文献情報:
    Rojas D et al. IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol. Lett. 2010 Aug;132(1-2):31-7
    Rojas D et al
    2010/01/01
  • 備考:
    Application: Flow Cytometry, Sample Type: Whole Cells
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Song X et al. Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol. Rep. 2014 Mar;31(3):1191-8
    Song X et al
    2014/01/01
  • 備考:
    Application: IHC Paraffin-embedded, Sample Type: Whole Tissue
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Kammerer-Jacquet SF et al. Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urol. Oncol. 2017 10;35(10):603.e7-603.e14
    Kammerer-Jacquet SF et al
    2017/01/01
  • 備考:
    Species: Human, Applications: IHC-P
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Zhou J et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 2017 Jun;5(6):480-492
    Zhou J et al
    2017/01/01
  • 備考:
    Species: Human, Applications: ELISA Capture
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Cristiani CM et al. Accumulation of Circulating CCR7<sup>+</sup> Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunol Res 2019 05;7(5):841-852
    Cristiani CM et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kammerer-Jacquet SF et al. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. Int. J. Cancer 2017 Jan;140(1):142-148
    Kammerer-Jacquet SF et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Giampieri R et al. Clinical impact of different exosomes&quot; protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE 2019;14(5):e0215990
    Giampieri R et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Mazel M et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015 Nov;9(9):1773-82
    Mazel M et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Mocan T et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol 2021 May;94:107467
    Mocan T et al
    2021/01/01
  • 備考:
    Species: Human, Applications: IHC
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Acheampong E et al. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells 2020 10;9(11)
    Acheampong E et al
    2020/01/01
  • 備考:
    Species: Human, Applications: IHC
  • 参照:
    PubMed